230 related articles for article (PubMed ID: 33739165)
1. Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis.
Han J; Wang Z; Liu C
Future Oncol; 2021 Jun; 17(17):2257-2274. PubMed ID: 33739165
[No Abstract] [Full Text] [Related]
2. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
3. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
[TBL] [Abstract][Full Text] [Related]
4. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.
Markar SR; Bodnar A; Rosales J; Song G; Low DE
Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
6. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.
Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577
[TBL] [Abstract][Full Text] [Related]
8. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.
Jing SW; Qin JJ; Liu Q; Zhai C; Wu YJ; Cheng YJ; Czito BG; Wang J
Future Oncol; 2019 Jul; 15(20):2413-2422. PubMed ID: 31269806
[No Abstract] [Full Text] [Related]
9. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
10. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
11. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
12. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.
Li F; Ding N; Zhao Y; Yuan L; Mao Y
Int J Surg; 2018 Dec; 60():88-100. PubMed ID: 30389537
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus.
Visser E; Edholm D; Smithers BM; Thomson IG; Burmeister BH; Walpole ET; Gotley DC; Joubert WL; Atkinson V; Mai T; Thomas JM; Barbour AP
J Surg Oncol; 2018 Jun; 117(8):1687-1696. PubMed ID: 29806960
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients.
Bosch DJ; Wang D; Nijsten MW; Mul VE; Hospers GA; Burgerhof JG; Struys MM; Plukker JT
Am J Surg; 2016 Jul; 212(1):89-95. PubMed ID: 27036621
[TBL] [Abstract][Full Text] [Related]
15. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
[TBL] [Abstract][Full Text] [Related]
17. An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma.
Cools-Lartigue J; Markar S; Mueller C; Hofstetter W; Nilsson M; Ilonen I; Soderstrom H; Rasanen J; Gisbertz S; Hanna GB; Elliott J; Reynolds J; Kisiel A; Griffiths E; Van Berge Henegouwen M; Ferri L
Ann Surg; 2022 Nov; 276(5):799-805. PubMed ID: 35861351
[TBL] [Abstract][Full Text] [Related]
18. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis.
Guo Y; Xu M; Lou Y; Yuan Y; Wu Y; Zhang L; Xin Y; Zhou F
PLoS One; 2022; 17(8):e0271242. PubMed ID: 35930539
[TBL] [Abstract][Full Text] [Related]
19. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
[TBL] [Abstract][Full Text] [Related]
20. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]